Nuwellis Receives Significant Funding for Pediatric Innovation
Nuwellis Inc. has announced a major advancement in pediatric health care with the receipt of a multi-year grant from the National Institutes of Health (NIH). The funding, totaling approximately $3 million, is aimed at expediting the development of Vivian™, a continuous renal replacement therapy (CRRT) device tailored specifically for young patients.
The Need for Pediatric-Specific Solutions
In the realm of pediatric care, particularly for infants and small children weighing under 20 kilograms, the options for renal support therapies have been notably limited. Often, clinicians are faced with the challenge of adapting adult technologies for these vulnerable patients, leading to potential complications. Nuwellis aims to fill this gap through the development of Vivian™, which is designed with a pediatric focus to ensure precise and gentle fluid management for this sensitive population.
Advancing the Vivian™ System for Young Patients
Vivian™ is intended to serve patients who fall between the 2.5 kg to 20 kg range, where appropriate treatment options are few and far between. The device seeks to offer an innovative solution that uses advanced technology to provide the necessary support to those suffering from kidney failure. With a pediatric-specific approach, Vivian™ is set to redefine fluid management in the critical care environment.
Technological Enhancements and Regulatory Pathways
The NIH grant will not only facilitate the technical development of the Vivian™ system but will also aid in advancing the software and firmware that enhance Nuwellis' broader portfolio. This includes building on the existing Aquadex SmartFlow® technology, which is currently utilized for adult patients and those above 20 kg. The goal is to ensure that Vivian™ is not only effective but also ready for an investigational device study to obtain US regulatory clearance.
Leadership Insights on Pediatric Care Needs
John Erb, the Chief Executive Officer of Nuwellis, emphasized the importance of developing therapies specifically designed for children. He stated, "Every conversation with a pediatric ICU team brings us back to the same truth — families need options that were built for their child, not borrowed from adult care." The funding from NIH is critical as it will enable Nuwellis to finalize essential software and firmware development, conduct initial studies, and streamline Vivian™ towards commercial viability.
Collaboration and Intellectual Property Rights
Under this collaborative effort, Koronis Biomedical Technologies Corporation (KBT) will oversee the program’s management and fund distribution, while Nuwellis retains complete ownership of the technology and the associated intellectual property developed. Ultimately, this partnership will foster an environment where innovation thrives, maximizing the potential for Vivian™ and Nuwellis' future growth.
About the Vivian™ Pediatric CRRT System
Vivian™ represents a groundbreaking advancement in pediatric renal replacement therapy. It features an adaptable design that meets the needs of neonates and children, with a targeted extracorporeal blood volume of 29–67 mL. This unique system includes real-time monitoring sensors, allowing for enhanced patient safety and therapeutic effectiveness. Additionally, the system's intuitive interface enhances clinician experience, dramatically reducing the learning curve and setup time.
About Nuwellis and Its Commitment to Innovation
Nuwellis, Inc. is dedicated to transforming patient care through innovative medical devices aimed at addressing fluid overload. With headquarters in Minneapolis and an operational subsidiary in Ireland, the company continues to strive for excellence in fluid management solutions with a focus on pediatric needs. By commercializing the Aquadex SmartFlow® system, Nuwellis is not only improving treatment options for children but also enhancing the overall portfolio for adult patients.
Frequently Asked Questions
What is the purpose of the NIH grant awarded to Nuwellis?
The NIH grant will accelerate the development of Vivian™, a CRRT device tailored for pediatric patients, enhancing fluid management options for young patients with renal failure.
How does Vivian™ differ from existing CRRT devices?
Vivian™ is specifically designed for patients under 20 kg, addressing the unique challenges faced by this demographic, unlike many existing devices which are designed for adults.
What role does Koronis Biomedical Technologies Corporation play in this project?
KBT will manage the program and distribute the grant funds while ensuring that Nuwellis retains full ownership of the technology and its intellectual property.
How will the development of Vivian™ impact the pediatric healthcare sector?
By providing a dedicated solution for pediatric patients, Vivian™ aims to improve outcomes and create more tailored treatment options for children suffering from fluid overload.
When can we expect Vivian™ to be commercially available?
As the grant supports initial investigations and development, the timeline for commercialization will depend on the success of these studies and the subsequent regulatory clearance process.
